All Brands Owned by Viatris Inc.

What does Viatris own?
Viatris owns the Lipitor, Viagra, Xanax, and Eliquis brands, along with a portfolio of over 1,400 approved generic molecules across cardiovascular, respiratory, central nervous system, oncology, immunology, and other therapeutic areas. The company also has a pipeline of complex generics and biosimilars. Its product portfolio was formed through the merger of Upjohn (Pfizer's legacy brand-name drug business) and Mylan (a global generic pharmaceutical company).

Is Viatris publicly traded?
Yes, Viatris Inc. is publicly traded on the Nasdaq stock exchange under ticker VTRS. The company has a dispersed shareholder base with institutional investors holding the majority of shares. Pfizer distributed its Viatris shares to Pfizer shareholders in 2021 and no longer holds a significant ownership stake. Viatris returned more than $1 billion to shareholders in 2025 through share repurchases and dividends.

Who founded Viatris?
Viatris was not founded by individuals. It was created in November 2020 through the merger of Upjohn, a division of Pfizer that held legacy brand-name drugs, and Mylan, a global generic pharmaceutical company founded in 1961 in White Sulphur Springs, West Virginia. The merger combined Upjohn's brand-name portfolio with Mylan's generic manufacturing capabilities to form a new company focused on providing access to affordable medicines.

Where is Viatris headquartered?
Viatris is headquartered in Canonsburg, Pennsylvania, USA. The company maintains its corporate offices in Pennsylvania and operates manufacturing facilities, distribution centers, and sales offices across the world. Its manufacturing network includes facilities in the United States, India, Europe, and China.

How many brands does Viatris own?
Viatris owns four key brand-name medicines: Lipitor, Viagra, Xanax, and Eliquis. The company also owns a portfolio of over 1,400 approved generic molecules across multiple therapeutic areas. In 2025, the company generated approximately $324 million in new product revenues and expects $450 million to $550 million in new product revenues in 2026 from its pipeline of generic and complex generic products.

Who owns Viatris?
Viatris is a publicly traded company with a dispersed shareholder base. Institutional investors, including mutual funds and investment firms, hold the majority of shares. No single shareholder has controlling ownership. Pfizer, the former parent of Upjohn, distributed its Viatris shares to Pfizer shareholders in 2021 and no longer holds a significant stake. The company is governed by a board of directors with independent representation.

What are Viatris's largest brands?
Lipitor and Viagra are Viatris's most recognizable brand-name products. Lipitor is a cholesterol-lowering statin medication originally developed by Pfizer. Viagra is an erectile dysfunction medication also originally developed by Pfizer. Xanax, an anti-anxiety medication, and Eliquis, an anticoagulant, are the company's other major brand-name products. Together, these brands contribute to the Developed Markets segment, which generated $8.5 billion in revenue in 2025.